01SOLVD-Treatment
One multicenter program (SOLVD-Treatment) randomized 2,569 people with symptomatic heart failure of all degrees and an ejection fraction of 35 percent or less. Follow-up ran up to 55 months. Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for heart failure. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.
Generic enalapril 10 mg x 90, GoodRx tablet table, 2026 board.
Generic enalapril 10 mg, ninety tablets - the strength sold abroad as Hypernil 10 mg, checked October 2026. GoodRx lists 10 mg x 90 at $79.78 average retail and $15.44 with a coupon. Ask the pharmacy to price thirty if that is what the prescription says. Kaelis Med does not dispense.
02CONSENSUS program
One program in people with NYHA Class IV heart failure and an enlarged heart on x-ray randomized 253 people. 127 people took VASOTEC. 126 people took placebo. At six months, survival was 74% on VASOTEC and 56% on placebo. At one year, survival was 64% on VASOTEC and 48% on placebo. People in both groups were usually also taking digitalis, a diuretic, or both.